InvestorsHub Logo

longusa

01/29/15 6:18 PM

#28799 RE: rrflyboy #28797

Yes, but even better, as pointed out by Flip a while ago, DCVax-Direct would be a more interesting combo as it provides:
- PhI data with multiple tumor types, with larger markets, showing efficacy
- More potent dose from more advanced manufacturing
- Much quicker regimen to full dosing. PhII will likely be 12-17 weeks for full 6 dose regimen whereas DCVax-L is 30 months for the 10 doses in a full regimen.

So my guess would be DCVax-Direct the more likely combo participant.